Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16186409 | 1.00 | CXCR2 (0.34) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL1768213 | 0.84 | CXCR2 (0.35) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL1924669 | 0.84 | CXCR2 (0.35) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL1768211 | 0.84 | CXCR2 (0.35) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL16584183 | 0.79 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL2797628 | 0.79 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL2598240 | 0.79 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL324715 | 0.76 | POLB (0.38) | CXCR2ALDH1A1L3MBTL1 | |
| SCHEMBL3761384 | 0.76 | CA12 (0.36) | CXCR2CXCR1 | |
| SCHEMBL324716 | 0.76 | POLB (0.38) | CXCR2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8877786-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8642635-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20130096168-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8377978-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20120202862-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8222286-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20110282075-A1 | METHOD FOR PREPARING VITTATALACTONE | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282075-A1 | METHOD FOR PREPARING VITTATALACTONE | FNTA, LCAT, AAAS | CXCR2 4076/4885CXCR1 2351/4885ALDH1A1 2817/4885 |
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | CXCR2 1321/4885CXCR1 1253/4885ALDH1A1 176/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | CXCR2 340/4885CXCR1 603/4885ALDH1A1 2474/4885 |
| US-20130096168-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | CXCR2 1321/4885CXCR1 1253/4885ALDH1A1 176/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | CXCR2 340/4885CXCR1 603/4885ALDH1A1 2474/4885 |
| US-20120202862-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | CXCR2 1321/4885CXCR1 1253/4885ALDH1A1 176/4885 |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | CXCR2 1315/4885CXCR1 1321/4885ALDH1A1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.